Research and Markets has released the report “Clinical Data Management in India”. This report provides an in-depth perspective of the sector from different aspects. Topics such as the CDM value chain, markets, major players, regulations, growth drivers, issues and challenges, critical success factors and merger trends are covered. The report also analyses the performance of the industry keeping in view the critical success factors.

AAIPharma, which provides clinical research management for the health care industry, has expanded its operations in Central and Eastern Europe with the addition of an experienced team in Hungary. The new office is in Budapest and will initially consist of seven staff. With two other offices in Central and Eastern Europe, operations in Croatia and Russia, and the recent addition of an office in South Africa, AAIPharma now has operations in 14 countries worldwide. Ludo Reynders, AAIPharma president and CEO, said: “Hungary with its population of ten million, good hospital infrastructure and the availability of patients is recognized as a key country in this region. As the needs of our biotechnology and pharmaceutical customers to run global clinical trials are ever increasing, it is important that we continue to expand our international presence in key regions such as this to meet these demands.”

The Department of Diagnostic Audiology at Children’s Hospital in Boston currently uses the wireless electronic data capture Mi-Forms software in conjunction with Fujitsu tablet PCs and a Perfect Pen implementation, which conveys the feel of writing on actual paper. The Boston facility’s move is part of a growing trend among hospitals, which are pushing for greater use of electronic medical records. Brian Fligor, director of the diagnostic audiology department, said that the solution saves time, resulting in more time with patients and better patient care. He added that the system also had the potential to reduce enough time off administrative and data entry duties to another 800 patients to be seen over 2008. 

The Michael J. Fox Foundation (MJFF) for Parkinson’s Research has suggested and identified several CROs (contract research organizations) to help applicants gather information essential for ensuring studies are appropriately designed to validate or invalidate targets, such as dosing amounts and brain bioavailability. The foundation has understood that discoveries will be a long time in coming to clinical trials if everything is left up to academics. Katie Hood, interim chief executive officer of MJFF, added: “Target Validation is emblematic of our Foundation’s aggressive, ‘get-it done’ approach to driving PD drug development and speeding delivery of treatments that can improve patients’ quality of life.”

Have a news release? Send it to .